Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2006-06-30
2010-06-01
Gupta, Anish (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S333000, C530S345000, C530S395000
Reexamination Certificate
active
07728106
ABSTRACT:
A method of making a synthetic glycopeptide, by addition of a synthetic oligosaccharide oxazoline to a GlcNAc-containing peptide precursor in the presence of an enzyme selected from among Endo-A and Endo-M. In a specific implementation, the method is utilized to synthesize a trivalent V3-domain glycopeptide including three V3-domain glycopeptides on a scaffold, wherein the three V3-domain glycopeptides are arranged to mimic the V3 domain presentation in trimeric gp120. Such trivalent V3-domain glycopeptides can be utilized in a vaccine for the treatment or prevention of HIV-1 infection.
REFERENCES:
patent: WO-2004/03366 (2004-04-01), None
GenBank: K03455.1.
Galanakis et al. (“Conformational Properties of HIV-1 gp120/V3 Immunogenic Domains,” Curr. Med. Chem., 2005, 12, 1551-1568).
GenBank K03455.1 “Human immunodeficiency virus type 1 (HXB2), complete genome; HIV1/HTLV-III/LAV reference genome” Oct. 21, 2002.
K. S. Cole et al.; Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3; J Virol; 2004; 78:1525-1539.
R. Pantophlet et al.; Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies; Trends Mol Med; 2003; 9:468-473.
S. E. O'Connor et al.; Modulation of protein structure and function by asparagine-linked glycosylation; Chem Biol; 1996; 3:803-812.
B. Imperiali et al.; Effect of N-linked glycosylation on glycopeptide and glycoprotein structure; Curr. Opin. Chem. Biol.; 1999; 3:643-649.
B. Imperiali et al.; Asparagine-linked glycosylation: speficity and function of oligosaccharyl transferase; Bioorg Med Chem; 1995; 3:1565-1578.
A. H. Andreotti et al.; Effects of glycosylation on peptide backbone conformation; J. Am. Chem. Soc.; 1993; 115:3352-3353.
R. Liang et al.; Sensitivity of glycopeptide conformation to carbohydrate chain length; J. Am. Chem. Soc.;1995; 117:10395-10396.
S. E. O'Connor et al.; A molecular basis for glycosylation-induced conformational switching; Chem Biol; 1998; 5:427-437.
S. E. O'Connor et al.; Probing the effect of the outer saccharide residues of N-linked glycans on peptide conformation; J Am Chem Soc; 2001; 123:6187-6188.
C. J. Bosques et al.; Effects of glycosylation on peptide conformation: a synergistic experimental and computational study; J Am Chem Soc; 2004; 126:8421-8425.
W. F. Vranken et al.; Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions; Eur J Biochem; 1996; 236:100-108.
W. F. Vranken et al.; Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution; Eur J Biochem; 2001; 268:2620-2628.
W. F. Vranken et al.; The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution; FEBS Lett; 1995; 374:117-121.
P. Catasti et al.; Structure and polymorphism of HIV-1 third variable loops; J Biol Chem; 1996; 271:8236-8242.
P. Catasti et al.; Local and global structural properties of the HIV-MN V3 loop; J Biol Chem; 1995; 270:2224-2232.
J. B. Ghiara et al.; Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site; J Mol Biol; 1997; 266:31-39.
A. Zvi et al.; Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy; Biochemistry; 1997; 36:8619-8627.
E. Cabezas et al.; A structure-based approach to a synthetic vaccine for HIV-1; Biochemistry; 2000; 39:14377-14391.
J. M. Rini et al.; Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen; Proc Natl Acad Sci; 1993; 90:6325-6329 U S A.
J. B. Ghiara et al.; Crystal structure of the principal neutralization site of HIV-1; Science; 1994; 264:82-85.
R. L. Stanfield et al.; Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop; Virology; 2003; 315:159-173.
R. L. Stanfield et al.; Structural rationale for the brand neutralization of HIV-1 by human monoclonal antibody 447-52D; Structure (Camb); 2004; 12:193-204.
I. Laczko et al.; Synthesis and conformational studies of N-glycosylated analogues of the HIV-1 prinicipal neutralizing determinant; Biochemistry; 1992; 31:4282-4288.
X. Huang et al.; Structural comparison of a 15 residue peptide from the V3 loop of HIV- 1IIIb and an O-glycosylated analogue; FEBS Lett; 1996; 393:280-286.
X. Huang et al.; Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135; Biochemistry; 1997; 36:10846-10856.
B. Chen et al.; Structure of an unliganded simian immunodeficiency virus gp120 core; Nature; 2005; 433:834-841.
B. Chen et al.; Determining the structure of an unliganded and fully glycosylated SIV gp120 envelope glycoprotein; Structure (Camb); 2005; 13:197-211.
P. D. Kwong et al.; Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody; Nature; 1998; 393:648-659.
O. Hartley et al.; V3: HIV's switch-hitter; AIDS Res Hum Retroviruses; 2005; 21:171-189.
M. K. Gorny et al.; Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody; J Virol; 1992; 66:7538-7542.
A. J. Conley et al.; Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D; J Virol; 1994; 68:6994-7000.
C. P. Krachmarov et al.; V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1; AIDS Res Hum Retroviruses; 2001; 17:1737-1748.
S. Zolla-Pazner et al.; The Cross-Clade Neutralizing Activity of a Human Monoclonal Antibody Is Determined by the GPGR V3 Motif of HIV Type 1; AIDS Res Hum Retroviruses; 2004; 20:1254-1258.
M. E. White-Scharf et al.; Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization; Virology; 1993; 192:197-206.
M. K. Gorny et al.; The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope; J Virol; 2004; 78:2394-2404.
P. D. Kwong et al.; Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus; J Virol; 2000; 74:1961-1972.
G. J. LaRosa et al.; Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant; Science; 1990; 249:932-935.
T. L. Hoffman et al.; HIV-1 envelope determinants for cell tropism and chemokine receptor use; Mol Membr Biol; 1999; 16:57-65.
C. D. Rizzuto et al.; A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding; Science; 1998; 280:1949-1953.
C. Rizzuto et al.; Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120; AIDS Res Hum Retroviruses; 2000; 16:741-749.
S. Basmaciogullari et al.; Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding; J Virol; 2002; 76:10791-10800.
M. Sharon et al.; Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity; Structure (Camb); 2003; 11:225-236.
A. Yonezawa et al.; Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1; J Virol; 2001; 75:4528-4267.
B. Nardelli et al.; A chemically defined synthetic vaccine model for HIV-1; J Immunol; 1992; 148:914-920.
H. X. Liao et al.; Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodefici
Bradley Christina
Fuierer Marianne
Gupta Anish
Moore & Van Allen PLLC
University of Maryland Biotechnology Institute
LandOfFree
HIV-1 glycopeptides and derivatives; preparation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV-1 glycopeptides and derivatives; preparation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-1 glycopeptides and derivatives; preparation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181262